4/1
06:12 am
idya
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events [Yahoo! Finance]
High
Report
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events [Yahoo! Finance]
4/1
06:00 am
idya
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
High
Report
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
3/31
06:23 am
idya
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma [Yahoo! Finance]
3/31
06:00 am
idya
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
Low
Report
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
3/28
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/26
06:28 am
idya
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor [Yahoo! Finance]
Low
Report
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor [Yahoo! Finance]
3/26
06:00 am
idya
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
Low
Report
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
3/3
06:27 am
idya
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets [Yahoo! Finance]
3/3
06:00 am
idya
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
Low
Report
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
2/28
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/14
11:48 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $50.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $50.00 price target on the stock.
2/13
06:49 am
idya
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
2/13
06:23 am
idya
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC [Yahoo! Finance]
Medium
Report
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC [Yahoo! Finance]
2/13
06:05 am
idya
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Medium
Report
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2/13
06:00 am
idya
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
Medium
Report
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
2/10
06:34 am
idya
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer [Yahoo! Finance]
Neutral
Report
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer [Yahoo! Finance]
2/10
06:21 am
idya
IDEAYA Biosciences names Joshua Bleharski as CFO [Seeking Alpha]
Neutral
Report
IDEAYA Biosciences names Joshua Bleharski as CFO [Seeking Alpha]
2/10
06:00 am
idya
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
Neutral
Report
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
1/31
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/27
06:00 am
idya
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
Low
Report
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
1/15
09:54 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock.
1/13
09:36 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/12
12:00 pm
idya
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
Medium
Report
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance